Coronary disease & ACSCohort study
Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions
- Registry-based cohort study
Authors' conclusion
In PCI patients, PFCS and platelet reactivity demonstrated important relationships in predicting clinical prognosis.
Study context
- Population
- Percutaneous coronary intervention (PCI)-treated patients, South Korean registry, January 2010 to November 2018
- Participants
- 2,512 patients
- Exposure
- Platelet reactivity and platelet-fibrin clot strength phenotypes
- Outcome
- MACE:
- All-cause death
- MI
- Stroke
- Follow-up
- Up to 4 years
Main finding
As reported in the abstract
MACE
Adjusted hazard ratio (95% CI)P value
HPR-PFCSHigh vs NPR-PFCSNormal
1.89(1.23–2.91)
P = 0.004HPR-PFCSHigh vs HPR-PFCSNormal
1.60(1.12–2.27)
P = 0.009- Additive effect of high platelet reactivity (HPR) and PFCSHigh on clinical outcomes (log-rank)
- P < 0.001
Observational data: associations, not effects.
Further findings
All-cause death
- Similar results as for major adverse cardiovascular event (MACE)
Safety
| Outcome | adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Major bleeding | 3.12 (1.30–7.69) | P = 0.010 | |
| 0.10.31310Adjusted hazard ratio (log scale) |
Original publication
Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J. Published 28 May 2024. doi:10.1093/eurheartj/ehae296
Summarised from the published abstract; every number is checked against it